Stockscreener 앱 받기
7.26
20.56%
1.23
전일 마감가:
$6.03
열려 있는:
$6.09
하루 거래량:
871.36K
Relative Volume:
1.72
시가총액:
$378.12M
수익:
-
순이익/손실:
$-117.81M
주가수익비율:
11.34
EPS:
0.64
순현금흐름:
$74.30M
1주 성능:
+4.60%
1개월 성능:
+77.32%
6개월 성능:
+116.37%
1년 성능:
+332.74%
1일 변동 폭
$6.06
$7.28
1주일 범위
$5.55
$7.28
52주 변동 폭
$1.66
$7.51
Omeros Corporation Stock (OMER) Company Profile
명칭
Omeros Corporation
전화
206-676-5000
주소
201 ELLIOTT AVENUE WEST, SEATTLE, WA
OMER을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| OMER | 7.25 | 378.12M | 0 | -117.81M | 74.30M | 0.64 |
| VRTX | 449.86 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.01 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.92 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.88 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.22 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-08 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-11-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-06-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-10-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2021-10-01 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-09-27 | 개시 | JP Morgan | Neutral |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-20 | 개시 | BofA Securities | Buy |
| 2020-08-21 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-14 | 재확인 | Maxim Group | Buy |
| 2019-05-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-12 | 개시 | Seaport Global Securities | Buy |
| 2018-03-23 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-03-05 | 다운그레이드 | Needham | Buy → Hold |
| 2017-11-08 | 개시 | H.C. Wainwright | Buy |
| 2017-05-11 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | 재확인 | Maxim Group | Buy |
| 2017-03-17 | 재확인 | Needham | Buy |
| 2016-11-16 | 재확인 | Wedbush | Outperform |
| 2016-11-10 | 재확인 | Needham | Buy |
| 2016-08-10 | 재확인 | Maxim Group | Buy |
| 2016-06-03 | 개시 | Cantor Fitzgerald | Buy |
| 2016-03-02 | 재확인 | Needham | Buy |
| 2016-02-29 | 재확인 | Wedbush | Outperform |
| 2015-11-11 | 재확인 | Needham | Buy |
| 2015-08-18 | 재확인 | WBB Securities | Strong Buy |
| 2015-08-10 | 개시 | ROTH Capital | Buy |
모두보기
Omeros Corporation 주식(OMER)의 최신 뉴스
Omeros nears resubmission of narsoplimab BLA - Investing.com
Omeros Corporation Provides Update on Progress Toward BLA Resubmission - Yahoo Finance
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN
StockNews.com Upgrades Omeros (NASDAQ:OMER) to Hold - MarketBeat
IgA Nephropathy Drugs Market: Driving Rapid Expansion with - openPR
Omeros Q3 2024Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns (OMER) - Seeking Alpha
Data Storage Corporation Reports 2024 Third Quarter Financial Results and Provides Business UpdateWASHINGTON, D.C. – Data Storage Corporation (NASDAQ: DTST) released its financial results for the third quarter ending September 30, 2024, and provi - Defense World
SigmaTron International, Inc. Announces Departure and Appointment of Chief Financial OfficerUNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_______________FORM 8-K_______________CURRENT REPORTPurs - Defense World
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN
Sydney high school parents vent frustration at plan for single-sex schools to become co-educational - ABC News
Omeros (NASDAQ:OMER) Upgraded at RODMAN&RENSHAW - MarketBeat
United States shares lower at close of trade; Dow Jones Industrial Average down 0.47% - Investing.com India
Omeros stock soars to 52-week high, hits $5.68 By Investing.com - Investing.com Canada
Earnings call: Omeros narrows Q3 loss, progresses key drug programs By Investing.com - Investing.com Australia
Earnings call: Omeros narrows Q3 loss, progresses key drug programs - Investing.com India
Omeros (OMER) Stock Rises After Reporting Q3Results - Stocks Telegraph
Omeros Shares Hit 52-Week High on Plan to Resubmit Narsoplimab Application - MarketWatch
U.S. Stock market top gainers: Omeros Corporation gains 52.99% while InflaRx N.V surges by 40.94% - Business Upturn
Rodman & Renshaw sets $9 target on Omeros stock with Buy rating - Investing.com
Omeros' (OMER) "Neutral" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Omeros stock soars to 52-week high, hits $5.68 - Investing.com
500: Something went wrong - Investing.com UK
U.S. Stock market top gainers: AgEagle Aerial Systems surges by 151.55% while Gaxos.ai Inc gains 47.58% in ealry trading - Business Upturn
Needham & Company LLC Reaffirms "Hold" Rating for Omeros (NASDAQ:OMER) - MarketBeat
Omeros initiated with a Buy at Rodman & Renshaw - TipRanks
Omeros (NASDAQ:OMER) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Omeros: Q3 Earnings Snapshot - New Haven Register
Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Adjustments - Yahoo Finance
Omeros Corporation Q3 2024 Financial Results Reviewed - TipRanks
Omeros up 4% as Q3 results beat on EPS - MSN
Omeros reports Q3 EPS (56c), two estimates (70c) - TipRanks
Q3 2024 Omeros Corp Earnings Call Transcript - GuruFocus.com
Omeros Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Omeros Q3 Loss Narrows to $32.2M, Advances Key Drug Programs Amid FDA Talks | OMER Stock News - StockTitan
Omeros Corporation Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
Blackline, Inc. Appoints Philippe Omer Decugis as Senior Vice President for Europe - Marketscreener.com
Earnings Outlook For Omeros - Benzinga
Omeros (OMER) Set to Announce Earnings on Wednesday - MarketBeat
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024 - Business Wire
Week Ahead In Pharmaceuticals: 5 Stocks To Watch (OMER, BOLD, XLRN...) - RTTNews
Omeros (NASDAQ:OMER) Stock Passes Above 200 Day Moving AverageHere's What Happened - MarketBeat
Cardiff City board to hold meeting with Omer Riza this weekend - Wales Online
Atypical Hemolytic Uremic Syndrome Drugs Market 2034: - openPR
NVIDIA Co. (NASDAQ:NVDA) Stock Holdings Increased by Alpha DNA Investment Management LLC - Defense World
Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Focal Segmental Glomerulosclerosis Drugs Market Report 2024FSGS Drugs Market Size - WhaTech
Global Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market to Reach USD 2308.84 Million by 20 - PharmiWeb.com
Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy - Pharmacy Times
OMEROmeros Corporation Latest Stock News & Market Updates - StockTitan
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy - Business Wire
Global Alcohol Use Disorder Treatment Market to Reach USD 1,300 million by 2033 at a 6.4% CAGR, Driv - PharmiWeb.com
Omeros Corporation (OMER) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):